100965-13-7

Basic information

• Product Name: 1H-Imidazole, 4,5-bis(4-bromophenyl)-
• CAS NO: 100965-13-7
• Molecular Formula: C15H10Br2N2
• Molecular Weight: 378.066
• Mol File: 100965-13-7.mol

Chemical Properties

• CAS DataBase Reference: 1H-Imidazole, 4,5-bis(4-bromophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole, 4,5-bis(4-bromophenyl)-(100965-13-7)
• EPA Substance Registry System: 1H-Imidazole, 4,5-bis(4-bromophenyl)-(100965-13-7)

Safety Data

• Hazardous Substances Data: 100965-13-7(Hazardous Substances Data)

Upstream product

• 35578-47-3 4,4'-dibromobenzil 
• 77287-34-4 formamide 
• 4254-18-6 1,2-bis(4-bromophenyl)-2-hydroxyethan-1-one 
• 1122-91-4 4-bromo-benzaldehyde 
• 50-00-0 formaldehyd 

Downstream Products

• 1280726-85-3 C₂₁H₂₂Br₂N₂ 
• 142217-44-5 ethyl 8-(4,5-di-(4-bromophenyl)imidazol-1-yl)-octanoate 

Relevant articles and documents

A new rhodium(I) NHC complex inhibits TrxR: In vitro cytotoxicity and in vivo hepatocellular carcinoma suppression

Thioredoxin reductase (TrxR) is often overexpressed in different types of cancer cells including hepatocellular carcinoma (HCC) cells and regarded as a target with great promise for anticancer drug research and development. Here, we have synthesized and characterized nine new designed rhodium(I) N-heterocyclic carbene (NHC) complexes. All of them were effective towards cancer cells, especially complex 1e was more active than cisplatin and manifested strong antiproliferative activity against HCC cells. In vivo anticancer studies showed that 1e significantly repressed tumor growth in an HCC nude mouse model and ameliorated liver lesions in a chronic HCC model caused by CCl4. Notably, a mechanistic study revealed that 1e can strongly inhibit TrxR system both in vitro and in vivo. Furthermore, 1e promoted intracellular ROS accumulation, damaged mitochondrial membrane potential, promoted cancer cell apoptosis and blocked the cells in the G1 phase.

Cd(II)-MOF-IM: Post-synthesis functionalization of a Cd(II)-MOF as a triphase transfer catalyst

A robust and porous Cd(ii)-MOF based on a bent imidazole-bridged ligand was synthesized and post-synthetically functionalized with linear alkyl chains to afford imidazolium salt (IM)-type triphase transfer catalysts for organic transformations. The imidazolium salt decorated Cd(ii)-MOF-IM exhibits typical solid phase transfer catalytic behavior for the azidation and thiolation of bromoalkane between aqueous/organic phases. Moreover, they can be easily recovered and reused under the PTC conditions. Cd(ii)-MOF-IM herein created a versatile family of solid phase transfer catalysts for promoting a broad scope of reactions carried out in a biphasic mixture of two immiscible solvents.

Synthesis and in vitro anticancer activities of selenium N-heterocyclic carbene compounds

Fourteen novel selenium N-heterocyclic carbene (Se-NHC) compounds derived from 4,5-diarylimidazole were designed, synthesized, and evaluated as antiproliferative agents. Most of them were more effective toward A2780 ovarian cancer cells than HepG2 hepatocellular carcinoma cells. Among them, the most active compound 2b was about fourfold more active than the positive control ebselen against A2780 cells. In addition, this compound displayed twofold higher cytotoxicity to A2780 cells than to IOSE80 normal ovarian epithelial cells. Further studies revealed that 2b could induce reactive oxygen species production, damage mitochondrial membrane potential, block the cells in the G0/G1 phase, and finally promote A2780 cell apoptosis.

Application of N-heterocyclic carbene selenium-gold compound in preparation of carbapenem-resistant acinetobacter baumannii drug

The invention discloses application of an N-heterocyclic carbene selenium-gold compound in preparation of a novel antibacterial drug resistant to carbapenem acinetobacter baumannii infection, and belongs to the technical field of drug preparation. According to the N-heterocyclic carbene selenium-gold compound, selenium-containing imidazole N-heterocyclic carbene selenium is used for replacing a thiosaccharide ligand in a gold nofen structure; the reaction activity of Au-Se in the N-heterocyclic carbene selenium-gold compound is higher than that of an Au-S bond, so that the Au-S bond in a Jinnofen structure can be prevented from being easily damaged by reducing mercaptan to a certain extent; and toxic and side effects are caused by metabolism before reaching a target spot. In-vitro antibacterial activity shows that IC50 of the compounds H7 and H8 in inhibition of carbapenem-resistant acinetobacter baumannii is 3.34 mu M and 4.67 mu M, MIC of the same are both 10 mu M, and MBC of the same are both 20 mu M. The animal in-vivo administration also shows a good anti-drug-resistant bacterium effect, which proves that the compound can significantly prolong the survival time of mice infected by drug-resistant bacteria, and has important practical application value.

Specific group modified N1 and N3 substituted 4,5-diaryl imidazole ring carbine rhodium complex and preparation method and application thereof

The invention discloses a specific group modified N1 and N3 substituted 4,5-diaryl imidazole ring carbine rhodium complex and a preparation method and application thereof. The structure of the rhodiumcomplex is shown as the formula II (please see the specification for the formula II), wherein R1 is selected from halogen, and C1-4 alkoxy or aryl, R2 is selected from C1-4 alkyl, and substituted ornon-substituted C1-4 alkyl, and a substituent group is selected from an aromatic ring or C3-6 cycloalkyl. In-vivo experiments show that the tumor growth inhibition rate of the rhodium complex under the dosage of 10 mg.kg can reach 45%, and the rhodium complex has the very high tumor growth inhibition capability and high safety, and has good application prospects in the aspect of developing novel non-platinum efficient anticancer drugs.

(II) based on the Co metal organic framework and its preparation method and application

The invention discloses an organic ligand L for synthesizing a Co (II) based metal organic framework, a Co (II) based metal organic framework Co-MOF-1 and a Co (II) based metal organic framework Co-MOF-2. The metal organic framework Co-MOF-1 is synthesized by virtue of the ligand L at first, and then crystals of the Co-MOF-1 are placed in the air for 24 hours at room temperature and then are subjected to constant-temperature treatment for 2 hours at 70 DEG C to obtain a novel catalyst Co-MOF-2 with active spots. The catalyst can be used for effectively catalyzing cyclohexane oxidation reaction, and a heavy metal is not needed to serve as a catalyst for reaction, so that the harm of the heavy metal to the environment is reduced, the reaction temperature is mild, the reaction time is relatively short, the usage amount of the catalyst is small, other additives are avoided, and the catalyst can be repeatedly used for more than 5 times relative to a free heavy metal salt.

A recyclable, self-supported organocatalyst based on a poly(N-Heterocyclic Carbene)

We report the synthesis and catalytic activity of a polymeric imidazolium salt. In contrast to the well-known resin-supported N-heterocyclic carbenes (NHCs), the material described herein affords a polymer with NHCs orthogonally positioned along a main chain upon generation in situ. The unique structural characteristics of the corresponding poly(NHC)s enabled the materials to display catalytic activities that were similar or superior to those displayed by monomeric analogues. Moreover, the new catalyst was successfully recovered and reused with minimal loss of performance over several cycles.(Figure Presented)